Introduction
Imaging is a key aspect of cancer diagnosis and staging, underpinning patient stratification, the selection of appropriate therapies and their subsequent management.
Currently morphological imaging is the standard, with lesion diameter according to RECIST (Response Evaluation Criteria in Solid Tumours) criteria [1] forming the mainstay of subsequent follow-up. However, mere measurement of lesion size is a poor indicator of the nature of the lesion, whether it represents viable or necrotic disease, whether it is rapidly proliferative or dormant, or of its metastatic potential, all of which determine outcome. Functional imaging approaches have the potential to more accurately characterise disease, and identify its extent, but there are a range of new techniques being developed that require validation for specific applications.
Careful selection of the most appropriate state-of-the-art imaging techniques therefore is essential for cancer assessment in the clinic.
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Evaluating the primary site
Morphological techniques such as Computed Tomography (CT) and Magnetic
Resonance Imaging (MRI) are the commonest diagnostic techniques used to stage cancer, detect enlarged lymph nodes, and lung or liver metastases. Functional imaging techniques such as Positron Emission Tomography (PET) with 2-[fluorine-1]fluroro-2-deoxy-D-glucose (FDG), also is used in staging some cancers e.g. lung and lymphoma [2, 3] . In pelvic tumours however, MRI is superior to other imaging modalities for evaluating disease extent and is now an integral part of preoperative assessment in rectal, cervical and prostate tumours [4, 6] . Although most MRI examinations are carried out using external coils, signal to noise ratio (SNR) of an MR signal can be dramatically improved by matching the coil size with that of the target by placing the coil as close as possible to the area of interest. Endorectal MRI is routinely used to assess prostate cancer. Preoperative assessment with endovaginal MRI allows detection of small (≤ 1cm
3 ) cervical tumours (sensitivity 87%, specificity 65%) and identifies the extent of parametrial spread (sensitivity 80%, specificity 91.3%) [7] .
Application of diffusion sensitising gradients to the MR pulse sequence provides image contrast through measurement of the diffusion properties of water within tissues. In a highly cellular tissue, extracellular water would not be able to diffuse far during the MR observation period without being blocked by structural interfaces such as cell membranes; this would lead to a short diffusional path and a reduced apparent diffusion coefficient (ADC [31] . It is likely that evidence will grow for the role of 18 FDG-PET and more disease specific PET tracers in detecting small volume recurrence before conventional imaging in many tumour types -as this happens the sensitivity may well surpass our understanding of the clinical implications of these findings and suitable strategies will have to be designed.
Evaluating metastatic disease
Surgical assessment of lymph nodes is still considered the gold standard but is costly, time consuming and can increase risks to the patient [16] [17] [18] . CT and MRI can be used to detect lymph node metastasis but cannot differentiate between benign and metastatic nodes. Ultra small particles of iron oxide (USPIOs) are lymph node specific contrast agents that can be administered intravenously to detect node metastases with MRI [19] . The particles are normally taken up by macrophages in the reticuloendothelial system of normal lymph nodes [20] which results in signal intensity loss in T 2 -W and T 2 *-W images due to the susceptibility artefact from iron. [32] . DW-MRI is also very useful for lesion detection and assessment of response to treatment [33, 34] and there is evidence to suggest that the combination of Mn-DPDP MR imaging and DW-MRI results in even higher diagnostic accuracy [35] .
Ultrasound contrast agents can be used to characterise lesions but at the moment it cannot rival the 3D volume acquisitions of CT and MR [36] . Intraoperative contrast enhanced ultrasound however, has been shown to have a significant impact on surgical strategy compared to conventional intraoperative ultrasound [37] .
Prediction and early monitoring of treatment response
In addition to conventional morphological and contrast enhanced studies, DWI-MRI is being widely used to assess treatment response [38] [39] [40] where changes due to cell swelling and apoptosis are measurable as changes in ADC at an earlier stage than subsequent conventional radiological response indicators. An increase in ADC values early after treatment initiation is associated with a subsequent reduction in tumour volume: a clear, substantial, and early increase in the ADC after successful therapy in drug sensitive breast tumors treated with Paclitaxel was potentially of great value in identifying response within a much shorter time scale than the associated changes in gross tumour volume [41] ; in liver lesions <8cm 3 in volume at presentation, DW-MRI predicted response by 4 or 11 days after commencement of therapy [42] . These observations are thought to be associated with an initial decrease in tumour cellularity in response to cell kill (and subsequent increase in extracellular space) reflected in an increase in tumour ADC value. Furthermore pre-treatment ADC values of primary and metastatic malignant brain lesions have been shown to predict response to radiotherapy: tumours with higher ADCs respond less favourably [43] .
Similarly, in patients with locally advanced rectal cancer, low mean pre-treatment tumour ADC predicted for a larger percentage size change of tumours after chemotherapy [44] . These results are consistent with the hypothesis that a high ADC may be indicative of tumour necrosis and consequently greater resistance to treatment.
Future perspectives
As tumour hypoxia causes stress-induced cellular responses and reduces the effectiveness of many therapies, non-invasive hypoxia measurements are being explored to enable refinements in treatment planning, e.g. dose-boosting hypoxic areas of potential radiation resistance with intensity modulated radiotherapy (IMRT). 
